5 news items
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)
ITCI
7 Aug 24
(NASDAQ:ITCI) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
ITCI
7 Aug 24
are also being assessed.ITI-1020 cancer immunotherapy program: Our Phase 1 single ascending dose study in healthy volunteers is ongoing
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
ITCI
22 Jul 24
analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
ITCI
18 Jun 24
in depression. It assesses nine key symptoms of depression: insomnia/hypersomnia, low mood, appetite/weight changes, impaired self-perception, concentration
Where Intra-Cellular Therapies Stands With Analysts
ITCI
12 Jun 24
into analysts' perspectives on the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values
- Prev
- 1
- Next